

P 01	HPV disease and COVID-19	
P 01-1	New concepts of cervical screening and follow-up during the COVID-19 pandemic in China	H. Y. Chuang (China)
P 02	Viral and molecular biology	
P 02-1	• Cartilage-hair hypoplasia (CHH) and risk for HPV related lesions	R. Ellonen (Finland)
P 02-3	 Viral whole-genome sequencing reveals high variations in APOBEC3-editing between HPV risk categories 	V. M. Ferré (France)
P 03	Epidemiology and natural history	
P 03-1	 Prevalence of HPV-16 variants in the anogenital region of men: the HIM study 	L. Sichero (Brazil)
P 03-3	• Duration of an oral HPV infection in men from the U.S. and Latin America	B. Dickey (USA)
P 03-4	Prevalence of human papillomavirus (HPV)-associated head and neck cancer by geography: a systematic literature review	A. Donohue (USA)
P 03-5	Targeted Literature Review: risks of HPV infection and diseases in individuals with autoimmune diseases	M. Labib (France)
P 03-6	Geotropism and oncogenic potential of HPV infections in cohort study populations in Vojvodina, north region of Serbia	A. Mandic (Serbia)



P 04	Pathogenesis	
P 04-1	Oncogenic interactions between HPV E6 and Aurora B: a novel therapeutic target?	P. Chan (China)
P 06	HPV prophylactic vaccines	
P 06-1	 Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis 	M. Kyrgiou (UK)
P 06-2	• Impact of catch-up HPV vaccination	M. Carlier (France)
P 07	HPV therapeutic vaccines	
P 07-1	 The effectiveness of the combined treatment of potassium-titanyl phosphorous (KTP) laser resection and adjuvant human papillomavirus (HPV) vaccination for laryngeal papillomatosis: a preliminary study 	J-H. Cho (South Korea)
P 07-2	 Suppression of inhibitory receptors of CD8 T cell and expression of chemokine receptor eradicated effectively cervical cancer in mouse 	S-J. Lee (South Korea)
P 07-3	 Prevention of HPV reinfection with HPV vaccination after laser vaporisation and conization in reproductive age patients with HSIL 	S. Khundadze (Georgia)



P 08	Immunotherapy - Immuno-oncology - New treatn	nents
P 08-1	• The impact of PIK3CA mutations on HPVE7 expression, PD-L1 (CD274) expression in HPV16 cervical SCC	H. Lou (USA)
P 09	Epidemiology and natural history	
P 09-1	 HPV- negative premalignant and malignant changes in the cervix: myth or reality 	R. Zivadinovic (Serbia)
P 09-2	 Association between common vaginal and HPV infections and results of cytology test in the Macedonian women 	I. Aleksioska Papestiev (North Macedonia)
P 09-3	 Evaluation of the HPV Selfy Extended assay for HPV genotyping of anal cytological specimens 	M. G. Dona (ltaly)
P 09-4	 Impact of cut off values for Onclarity™ HPV assay in clinical testing 	A. V. R. Norén (Norway)
P 09-5	 Pre-vaccination prevalence of high-risk human papillomaviruses (hrHPV) in the Montenegro prior to national HPV immunisation programme: baseline for monitoring the efects of immunisation 	M. Govedarica (Montenegro)
P 09-6	High-grade cervical lesions at start of screening age in Danish women HPV-vaccinated as girls	M. Hartmann Nonboe (Denmark)
P 09-7	 Comparison of Allplex HPV detection using cervical specimens, the fast and comprehensive assays suitable for HPV screening and genotyping 	S. W. A. An (South Korea)
P 09-8	• HPV genotyping using Allplex™ hrHPV detection in paired physician- (Rhinprep® liquid-based cytology) and self-collected (evalyn brush) vagino-cervical specimens	V. López-Codony (Spain)



P 10	HPV screening	
P 10-1	• 14 hrHPV detection: the Lazio experience in the national HPV- based cervical cancer screening in Italy	M. Cenci (ltaly)
P 10-2	 Cervical intraepithelial neoplasia in non-16/18 high-risk HPV positive/cytology negative women: an alternative approach in poor resource areas 	F. Yarandi (Iran)
P 10-3	 Performance evaluation of the COBAS® 5800 system and comparison to the COBAS® 6800/8800 systems for clinical validation of COBAS® HPV 	C. Kay (USA)
P 10-4	 Increase of cervical cancer prevention in the Czech Republic using self-sampling 	K. Vladimira (Czech Republic)
P 10-5	Distribution of self-sampling device among Czech women targeted by the cervical cancer screening program	H. Jaworek (Czech Republic)
P 10-6	High-risk HPV infection in Albanian women and some factors associated with it	M. Mino Rista (Albania)
P 11	Screening for women difficult to reach	
P 11-1	Cervical human papillomavirus infection among vulnerable women in Rome, Italy: the Dorothy project	E. Giuliani (Italy)
P 12	Screening for women difficult to reach	
P 12-1	 Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Örebro, Sweden 	L. Bergengren (Sweden)



P 13	Self-sampling	
P 13-1	 HPV testing on self-collected vaginal and urine samples using Papilloplex® hrHPV DNA assay 	C. Cuschieri (UK)
P 13-2	 Copan universe permits automated preparation of vaginal self- collected swabs for HPV molecular testing 	A. Giambra (Italy)
P 13-3	 Pilot study: involvement of long-term non-attending population of Czech women in cervical screening program 	O. Bouska (Czech Republic)
P 13-4	 High acceptability and accuracy of self-collection by veil collector device for high risk-HPV screening by multiplex real- time PCR among adult women and men who have sex with men (MSM) living in Central Africa 	L. Belec (France)
P 13-5	 Validation of Colli-pee UCM FV-5004: a user-friendly device for volumetric first-void urine collection and HPV DNA preservation compatible with high-throughput instruments 	N. Meers (Belgium)
P 14	Genotyping	
P 14-1	 Performance of high risk HPV single analyte and multiplex panel external quality controls for verification of extended genotyping on the Onclarity™ HPV Assay 	M. Luscher (Canada)
P 14-3	HPV genotype in metastatic HPV induced penile squamous cell carcinoma	L. Dorofte (Sweden)



P 15	Molecular markers	
P 15-1	 CD39 and PD-1 expression on peripheral CD4+ lymphocytes is associated with anal pre-cancer among men with HIV 	S. Sudenga (USA)
P 15-2	Comparison of various prognostic markers and hrHPV expression in endocervical adenocarcinoma	X. Li (China)
P 15-3	The immumohistochemical characteristics of cervical glandular intraepithelial neoplasias	B. Jugeli (Georgia)
P 15-4	Epistasis between GSTM1, NOS3 and MTHFR genes in cervical carcinoma or precursor lesions	M. C. Bicho (Portugal)
P 16	Screening methods	
P 16-1	 Evaluation of the clinical detection of the human papillomavirus using two validated platforms: second interlaboratory study in Argentina 	E. A. Zubillaga (Argentina)
P 13-2	Glandular and metaplastic transformation zone cells in cervical cytology decline with age	A. B. Campaner (Brazil)
P 18	Methylation	
P 18-1	 HPV genotyping and methylation test in the liquid-based cytology of rare genital and anal lesions 	J. Nemcova (Czech Republic)



P 20	Serology	
P 20-1	 Establishment of a high-throughput liquid handling platform for the detection of high-risk oropharyngeal cancer serum antibody profiles 	L. Kröller (Germany)
P 22	Artificial intelligence	
P 22-1	 Can AI-based colposcopy replace conventional screening tests for cervical intraepithelial neoplasia? 	A. Cho (South Korea)
P 23	Diagnostic procedures / management	
P 23-1	 A combination of epigallocatechin gallate, folic acid, hyaluronic acid and vitamin B12 reverses condyloma growth and improves cervical lesion in a young caucasian woman 	E. Lepore (Italy)
P 23-2	 Effect of a coriolus versicolor-based vaginal gel for high-risk HPV clearance and cyto-normalization in a 44-year-old patient with hrHPV persitence of more than 10 years 	B. López-Cavanillas (Spain)
P 23-3	 Correlation between colposcopic patterns and histological grade of vaginal intraepithelial neoplasia (vain): a retrospective cohort study 	C. M. M. Matozzo (ltaly)
P 23-4	Clinical significance of cytological findings of atypical glandular cells: 10 years experience of a colposcopic referral centre	E. Di Loreto (ltaly)



P 25	Colposcopy	
P 25-1	 Colposcopy in women aged 65 years and older with normal cytology and persisting HPV infection 	E. Künkel (Germany)
P 25-2	 Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: a prospective cohort study 	M. Kiviharju (Finland)
P 25-3	 On-line certification platform for colposcopists engaged in cervical cancer screening programme in Poland 	A. Szczesna (Poland)
P 25-4	Different approach to colposcopic findings in pregnancy	M. Perisic Mitrovic (Serbia)
P 26	Cervical neoplasia	
P 26-1	 Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: up to 14 years of recorded follow-up 	D. Megyessi (Sweden)
P 26-2	Distribution of NK cells in microenvironment during the progression of cervical intraepithelial neoplasia	K. Manjgaladze (Georgia)
P 26-3	 The role of HPV type in patients with early stage cervical cancer who undergoing fertility-sparing laparoscopic radical trachelectomy 	JY. Park (South Korea)
P 27	Vulvar and vaginal diseases and neoplasia	
P 27-1	 Sequencing of HPV-positive and negative vulvar carcinomas using the oncomine comprehensive assay 	G. Lillsunde Larsson (Sweden)
P 27-2	High-grade vaginal intraepithelial neoplasia and recurrence risk: analysis of an Italian regional referral center series	E. Monti (ltaly)
P 27-3	 Central sensitization in vulvodynia and endometriosis: what have we been overlooking so far? 	G. E. Cetera (Italy)



P 28	Anal neoplasia	
P 28-1	Anal high-grade intraepithelial neoplasia in women with cervical high-grade intraepithelial neoplasia	A. Viscardi (ltaly)
P 28-2	Anal precancer detection by high-resolution microendoscopy by combined with HPV testing	M. Gaisa (USA)
P 30	HPV and oropharynx / Head and neck cancer	
P 30-1	 Circulating tumour HPV16 DNA at the commencement and completion of the radiotherapy in patients with p16 positive oropharyngeal cancer included in the ARTSCAN III study 	J. Sjövall (Sweden)
P 30-2	• High risk HPV in HIV-infected women - a case report	A. Pacheco (Portugal)
P 30-3	 Initial findings: a comprehensive meta analysis of the sociodemographic factors associated with head and neck cancer by HPV status 	S. Sutton (USA)
P 30-4	 Argentine consortium for the study of HPV in head and neck cancers: HPV genotyping and p16 INK4a staining 	M. Correa (Argentina)
P 30-5	 The lack of standardized outcomes for surgical salvage of human papillomavirus (HPV) positive recurrent oropharyngeal squamous cell carcinoma: a systematic scoping review 	A. N. Taniguchi (USA)
P 30-6	HOPE5 study: exploring new prognostic biomarkers for HPV-associated oropharyngeal cancer	F. Rollo (ltaly)
P 30-7	Artificial intelligence for image-based HPV status prediction in head and neck cancer: a systematic review and meta-analysis	Y-F. Li (China)



P 32	Genital warts	
P 32-1	 Colposcopic Magnified Scanning Laser Vaporization (CMSLV) for genital warts during pregnancy: a propsective descriptive evaluation of safety and reliability in a maternal care hospital 	R. Venzi (Italy)
P 32-2	• Economic burden of genital warts in Finland in 2018	A. Gylling (Finland)
P 34	Sexually transmitted diseases and HIV infection	
P 34-1	 Relation of HPV-related biomarkers expression and cervicovaginal infections in women of reproductive age harbouring cervical dysplasias in a colposcopic population 	G. Valasoulis (Greece)
P 35	Conventional therapies	
P 35-1	 Persistence and recurrence of CIN after LLETZ, with surgical pathological anatomology containing compromised margins, in a Brazilian university hospital service 	N. Speck (Brazil)



P 37	Advocacy, acceptability and psychology	
P 37-1	 Home-based self-sampling of first-void urine for hrHPV testing in the casus study: attitudes and preferences from a Belgian colposcopy referral population 	J. Hendrickx (Belgium)
P 38	Health education	
P 38-1	The Cellular and Molecular Cytopathology Training School	H. Keegan
	(CMCTS) at Coombe Women's Hospital, Dublin	(Ireland)
P 39	(CMCTS) at Coombe Women's Hospital, Dublin Low resource settings	_



P 40	Epidemiology and natural history	
P 40-1	Reducing provider perceived barriers to HPV vaccination through a practice facilitation intervention	J. Canedo (USA)
P 40-2	 Cervical cancer risk factors and symptoms awareness in hard- to-reach populations in Bangladesh, India, Slovakia and Uganda 	M. Sultanov (Netherlands)
P 40-3	 Declines in vaccine-type human papillomavirus prevalence in US females across racial/ethnic groups: national health and nutrition examination survey 	R. Stefanos (USA)
P 40-4	 Accuracy of self-reported human papillomavirus vaccine using computer-assisted self-interview in young men who have sex with men 	E. Chow (Australia)
P 40-5	Evaluation of the impact of the new school-entry policy on HPV vaccination in PR	V. Colon-Lopez (Puerto Rico)
P 40-7	• Sexually transmitted infections and HPV molecular profile. A study of 336 women	A. Daponte (Greece)